Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03113188 · ClinicalTrials.gov registry record · Phase 1
CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors
A Phase 1 study, sponsored by CanBas Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT03113188: Completed Phase 1 study, sponsored by CanBas Co..
NCT03113188 is a Phase 1 study that has completed, run by CanBas Co.. The registered enrollment target is 47 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (22% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03113188, a Phase 1 study, has completed, sponsored by CanBas Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, phase 1b study of CBP501/cisplatin/nivolumab combination administered once every 21 days to patients with advanced solid tumors.
Primary Outcome
Define the recommended doses (RP2D) of CBP501, cisplatin and nivolumab when administered in combination once every 21 days in patients with previously treated advanced solid tumors
Interventions
- DRUG CBP501
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2017-10-25 |
| Est. Completion | 2021-02-15 |
| Phase | Phase 1 |
What the finished NCT03113188 record still lists
NCT03113188 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (22% lower).
The record links to 0 conditions, and to 1 intervention - of which CBP501 is the first listed.
NCT03113188 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03113188 about?
NCT03113188 is a clinical study titled "CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors". This is a multicenter, open-label, phase 1b study of CBP501/cisplatin/nivolumab combination administered once every 21 days to patients with advanced solid tumors.
What is the current status of trial NCT03113188?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2017-10-25. Estimated completion is 2021-02-15.
What interventions are being tested in trial NCT03113188?
The interventions under investigation include: CBP501 (DRUG).
Who is sponsoring clinical trial NCT03113188?
This trial is sponsored by CanBas Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03113188's enrollment target sits among peer trials
47 1053rd of 2000 higher than 943 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI